Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.28.06 | Endocrine tumours and neoplasia – NETS | ECE2015

Patient-reported time to diagnosis of neuroendocrine tumors (NETs) in Europe: results from the first global NET patient survey: a collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis

Pavel Marianne , Kolarova Teodora , Goldstein Grace , Leyden John , Sissons Maia

Background: Neuroendocrine tumor (NET) symptoms are often similar to common conditions or may not arise until metastasis occurs, delaying diagnosis and impacting survival. We present data on time to diagnosis from the European (EU) NET patient perspective.Methods: In 2014, 1928 NET patients from >12 countries (Europe (n=763): Belgium, Bulgaria, France, Germany, Norway, UK, and other EU countries (not specified); Americas; Asia; Oceania) part...

ea0052p16 | (1) | UKINETS2017

Relationship between symptoms and health-related quality of life benefits in patients with carcinoid syndrome: post-hoc analyses from TELESTAR

Pavel Marianne , Cella David , Beaumont Jennifer , Hudgens Stacie , Marteau Florence , Feuilly Marion , Gabriel Sylvie , Houchard Aude , Ramage John , Horsch Dieter , Kulke Matthew

Background: The safety and efficacy of telotristat ethyl (TE) in patients (pts) with metastatic neuroendocrine tumors (NETs) and carcinoid syndrome (CS) not adequately controlled with somatostatin analogs (SSAs) have been demonstrated. TE-treated pts showed significantly greater reductions in bowel movement (BM) frequency and more presented with durable response than placebo (PBO)-treated pts. These post-hoc analyses examined the relationship between improvements in symptoms a...

ea0049gp177 | Pituitary | ECE2017

Octreotide subcutaneous (s.c.) depot, a novel ready-to-use formulation, provides higher exposure and maintains response in patients with acromegaly and functioning neuroendocrine tumours (NETs) previously treated with long-acting octreotide: Results from a phase 2, open-label, multicentre, randomized study

Ferone Diego , Borson-Chazot Francoise , Cailleux Anne , Horsch Dieter , lahner Harald , Pivonello Rosario , Tauchmanova Libuse , Darstein Christelle , Olsson Hakan , Tiberg Fredrik , Pavel Marianne

Background: Octreotide s.c. depot is a novel, ready-to-use formulation administered via a thin needle, which may allow self-administration. In a phase 1 study in healthy volunteers, octreotide s.c. depot provided greater bioavailability with faster onset and greater IGF1 suppression than long-acting octreotide. Here, we present data from a phase 2 study evaluating pharmacokinetics (PK), efficacy, safety, and tolerability of octreotide s.c. depot in patients with acromegaly and...

ea0035p578 | Endocrine tumours and neoplasia | ECE2014

Antiproliferative effects of lanreotide Autogel in patients with enteropancreatic neuroendocrine tumours: results of CLARINET, a large international phase 3 study

Caplin Martyn , Ruszniewski Philippe , Pavel Marianne , Cwikla Jaroslaw , Phan Alexandria , Raderer Markus , Sedlackova Eva , Cadiot Guillaume , Wall Lucy , Rindi Guido , Langley Alison , Blumberg Joelle

Introduction: Data demonstrating antiproliferative effects of somatostatin analogs (SSAs) in enteropancreatic NETs are limited; only one prospective trial so far has shown this for patients with midgut tumors and low hepatic tumor load (HTL). CLARINET is the first large phase 3, randomized, placebo-controlled trial evaluating such effects for the SSA lanreotide in patients with non-functioning enteropancreatic NETs.Methods: Patients who had well/moderate...

ea0089t6 | Trials In Progress | NANETS2022

ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA

Hope Thomas , Mehr Samuel , Morris Michael , Li Daneng , Halperin, MD Daniel , Strosberg Jonathan , Soares Heloisa , Jacene Heather , Pavel Marianne , L. Kunz Pamela , Ferreira Denis , Li Joanne , Ma Kimberly , Rearden Jessica , Moran Susan , Singh Simron

Background: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are commonly characterized by overexpression of somatostatin receptor subtype 2 (SSTR2), which can be targeted by radiopharmaceutical therapy (RPT) via radiolabeled somatostatin analogues (SSAs). RYZ101 (Ac-225 DOTATATE) is a first-in-class, highly potent alpha-emitting RPT being developed for the treatment of SSTR2+ solid tumors. Alpha-particles (such as emitted by Actinium-225) have a sho...

ea0046p11 | (1) | UKINETS2016

Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews

Anthony Lowell , Horsch Dieter , Ervin Claire , Kulke Matthew H. , Pavel Marianne , Bergsland Emily , Caplin Martyn , Oberg Kjell , Warner Richard , Kunz Pamela , Metz David C. , Pasieka Janice , Pavlakis Nick , DiBenedetti Dana , Haydysch Emily , Yang Qi Melissa , Jackson Shanna , Arnold Karie , Law Linda , Lapuerta Pablo

Background: Telotristat etiprate (TE), an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome (CS) by reducing serotonin production. TE was evaluated in TELESTAR, a phase 3 study; the primary endpoint showed significant reductions in bowel movement (BM) frequency for 2 TE dosages + standard of care (SOC) vs. SOC. TELESTAR patients had CS inadequately controlled on somatostatin analog therapy with ≥4 BMs per day. They were interviewed about base...

ea0060p26 | (1) | UKINETS2018

Tumour growth rate (TGR) in neuroendocrine tumours (NETs): changes following systemic treatment and external validation of previous findings; the GREPONET-2 study

Lamarca Angela , Ronot Maxime , Moalla Salma , Crona Joakim , Opalinska Marta , Lopez-Lopez Carlos , Pezzutti Daniela , Najran Pavan , Carvhalo Luciana , Otaviano Franca Bezerra Regis , Borg Philip , Vietti-Violi Naik , Vidal-Trueba Hector , de Mestier Louis , Scaefer Niklaus , Baudin Eric , Sundin Anders , Costa Frederico , Pavel Marianne , Dromain Clarisse

Background: TGR represents the percentage change in tumour volume per month (%/m). Previous results from the GREPONET study (A. Lamarca et al, ENETS 2018) showed that TGR measured after 3 months (TGR3m) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in NETs.Methods: Pts from 7 centres with advanced grade (G) 1/2 NETs from the pancreas (P)/small bowel (SB) initiating ST...

ea0099oc7.2 | Oral Communications 7: Endocrine-related Cancer | ECE2024

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

Ferone Diego , Halperin Daniel , Myrehaug Sten , Herrmann Ken , Pavel Marianne , Kunz Pamela , Chasen Beth , Capdevila Jaume , Tafuto Salvatore , Oh Do-Youn , Yoo Changhoon , Falk Stephen , Halfdanarson Thorvardur R , Folitar Ilya , Zhang Yufen , Santoro Paola , Aimone Paola , de Herder Wouter W , Singh Simron

Background: There is no universally accepted first-line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Phase 3 NETTER-2 study (NCT03972488) evaluated [177 Lu]Lu-DOTA-TATE (hereafter177 Lu-DOTATATE) as 1L treatment in patients with grade (G)2 and G3 advanced GEP-NETs. This is the first trial to assess 1L radioligand therapy (RLT) in any solid tumor.Methods: Eligible pat...